News

A kidney relief  drug worth €673m
Enlarge image

BusinessSwedenUK

A kidney relief drug worth €673m

10.10.2012 - British-Swedish Astra Zeneca pays Californian start-up Ardelyx up to €673m to get hold on exclusive rights for their NHE3 inhibitor programme.

After a setback this summer with an anti-obesity drug, Astra Zeneca is trying to pick up pace by getting hold on a new class of drugs. The small molecules developed by Ardelyx from Fremont (USA) target a sodium transporter on the surface of the intestinal epithelia. Astra Zeneca sees promising options for the treatment of diseases ranging from cardiovascular defects to diabetes or chronic kidney problems. On 8 October, the two companies announced a worldwide exclusive licensing agreement for Ardelyx’s NHE3 inhibitor programme worth up to €673m. The lead compound – Phase 2-ready RDX5791 – showed activity against constipation-predominant irritable bowel syndrome (IBS-C) and is also clinically tested in end-stage renal disease (ESRD) and chronic kidney disease (CKD). Under the terms of the agreement, Astra Zeneca will pay €27m up-front. Development milestones could rinse another €184m into Ardelyx’ pockets. With launch and commercialisation milestones and tiered double-digit royalties, the whole deal could yield up to €673m. Ardelyx will fund Phase II trials and Astra Zeneca further clinical development.

Aside from RDX5791, several other compounds all targeting the main transporter of sodium in the intestines, NHE3, are also subject to the deal. The effect of RDX5791 can be compared with living on a low-salt diet. Preventing the uptake of sodium ions into the body unburdens failing kidneys to eliminate excess sodium. Blocked sodium will be excreted with the faeces instead. A positive systemic effect is that no sodium will accumulate in intravascular and interstitial tissues, so hypertension and oedema formation could be effectively averted. Beyond NHE3 inhibitors, Ardelyx has three separate non-systemic preclinical compounds that are all not covered by the Astra Zeneca deal. Although targeting different molecules in the gut, they share a common property in that they are not absorbed by the gastrointestinal epithelia and are passed through the gastrointestinal tract without being altered.

© eurobiotechnews.eu/ml

FincanceSwedenFrance

18.04.2014 Oxthera AB, a Swedish biopharma company with a focus on rare diseases, has gained a SEK70m cash injection to continue its clinical programme for primary hyperoxaluria.

FundingEU

17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

BioeconomyFranceEU

01.04.2014 The European Commission has approved a French state package aid worth €43m for green chemistry project IEED.

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • PHARMING (NL)0.53 EUR12.8%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • NICOX (F)2.44 EUR7.5%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • DEINOVE (F)12.96 EUR-5.3%

TOP

  • WILEX (D)0.92 EUR61.4%
  • BIOTECH PHARMACON (N)17.50 NOK59.1%
  • E-THERAPEUTICS (UK)28.00 GBP40.0%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-47.1%
  • PROTHENA PLC (IE)28.07 USD-41.9%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6221.0%
  • IXICO (UK)71.50 GBP810.8%
  • PHARMING (NL)0.53 EUR783.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.5%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 20.04.2014